subject: Mesothelioma and Immune Profile of Pleural Effusions [print this page] Conclusions: SS1P is well tolerated with pleuritis as the DLT at the highest dose level. Evidence of clinical activity was noted in a group of heavily pretreated patients. Phase II clinical trials of SS1P are being planned for malignant mesothelioma and other mesothelin-expressing malignancies."
Mesothelioma and Immune Profile of Pleural Effusions
By: Montwrobleski77
welcome to Insurances.net (https://www.insurances.net)
